ENGNenGene Therapeutics Inc.

1.50−1.86%· post 1.50

Mkt cap$102.5MRevenue—Revenue—

LXRXLexicon Pharmaceuticals, Inc.

1.42−4.05%· post 1.42

ClosedOct 30 '26

Mkt cap$631.8MRevenue$692,000Q2 FY26Revenue$144MFY25

Compare

ClosedOct 30 '26

ENGNenGene Therapeutics Inc.

LXRXLexicon Pharmaceuticals, Inc.

1.50−1.86%post 1.50

Price

1.42−4.05%post 1.42

$102.5M

Mkt cap

$631.8M

—

Revenue

$692,000Q2 FY26

—

Revenue

$144MFY25

ENGNenGene Therapeutics Inc.

Mkt capRevenueRevenue

LXRXLexicon Pharmaceuticals, Inc.

Mkt capRevenueRevenue

Compare

ENGNenGene Therapeutics Inc.

LXRXLexicon Pharmaceuticals, Inc.

Price

Mkt cap

Revenue

Earnings history

last 4 reports each · paired by recencyMethod

ENGN1 of 4 reports

Reportimpliedrealized× implied

Q3 FY26—+5.49%—

LXRX1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±22.0%−3.67%×0.17

= impliedENGN realized, solidLXRX realized, hatchedOne scale, both sides: full bar = 22%× = |realized| ÷ impliedSource: market data

ENGN compared with LXRX: revenue, margins and what each company keeps, and the suppliers and customers both name